Inventiva S.A. (EPA:IVA)

Market Cap	909.76M +108.4%
Revenue (ttm)	6.76M -52.0%
Net Income	-354.14M
EPS	-1.90
Shares Out	207.71M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	144,502
Average Volume	251,140
Open	4.500
Previous Close	4.380
Day's Range	4.500 - 4.630
52-Week Range	2.560 - 6.200
Beta	0.88
RSI	50.99
Earnings Date	Sep 25, 2026

About Inventiva

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-β, a pre-clinical program for the tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 77
• Stock Exchange: Euronext Paris
• Ticker Symbol: IVA

Financial Performance

In 2025, Inventiva's revenue was 6.76 million, a decrease of -52.03% compared to the previous year's 14.10 million. Losses were -354.14 million, 92.2% more than in 2024.